These results demonstrated that the expression of IL-17 was a significantly independent factor that may contribute to the recurrence of LC patients after adjustment with other significant confounders, including tumor size and TNM stage [38–40]. This evidence concerns the gene IL17A and laryngotracheoesophageal cleft.